MET and thyroid gland carcinoma: Also, there have been earlier reports that hepatocyte growth factor (HGF) and its receptor c-Met are overexpressed in thyroid cancer and HGF treatment increases thyroid cancer cell motility through overexpression of EMT markers [33–36].